GCG and type 2 diabetes mellitus: Most recently, the pharmaceutical company, Eli Lilly, presented impressive Phase 2 results in overweight patients with T2DM treated with tirzepatide, a mono-molecular, long-acting (weekly) GIP-GLP-1 co-agonist (7).